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ABSTRACT: The ability of dendritic cells to coordinate innate and adaptive immune responses makes them essential targets for
vaccination strategies. Presentation of specific antigens by dendritic cells is required for the activation of the immune system
against many pathogens and tumors, and nanoscale materials can be functionalized for active targeting of dendritic cells. In this
work, we integrated an immunogenic, carbohydrate melanoma-associated antigen-mimetic GM3-lactone molecule into
mannosylated peptide amphiphile nanofibers to target dendritic cells through DC-SIGN receptor. Based on morphological
and functional analyses, when dendritic cells were treated with peptide nanofiber carriers, they showed significant increase in
antigen internalization and a corresponding increase in the surface expression of the activation and maturation markers CD86,
CD83 and HLA-DR, in addition to exhibiting a general morphology consistent with dendritic cell maturation. These results
indicate that mannosylated peptide amphiphile nanofiber carriers are promising candidates to target dendritic cells for antigen
delivery.
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■ INTRODUCTION
The immune system is a complex machinery that requires
regulatory interplay between its innate and adaptive compart-
ments to ensure an efficient surveillance against pathogens and
cancer cells. Generally, the immune system is not efficiently
induced against tumors, and cancer cells are tolerated because
of the evasion mechanisms they employ.1 Because cancer cells
are poor antigen-presenting cells (APC), a robust antitumor
immune response cannot be elicited. Cancer immunotherapy
approaches aim to induce a long-lasting and robust immunity,
enabling cancer patients to fight against their own cancer. Thus,
understanding of cancer and immune system cross-interactions
holds a paramount importance for the improvement and
development of new cancer immunotherapy strategies.2,3
Dendritic cells (DCs)4 are promising candidates for cancer
immunotherapy, as they capture, process and present antigens
to T-cells for the initiation of adaptive immunity.5,6 T-cells
presented and activated with a tumor antigen initiate anticancer
responses. The activation of dendritic cells and their capability
to activate T cells depend on their maturation state,7 which is
determined by the upregulation of costimulatory molecules as
well as by morphological changes such as increased cell surface
area, which enables more connections with surrounding cells.8
Several attempts have been made to pulse DCs with specific
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antigens for the induction of anticancer immunity. The
targeting of C-type lectin receptors (CLR) is critical for the
pulsing and maturation of DCs.9,10 Among CLRs, dendritic cell
specific intracellular adhesion molecule-3-grabbing nonintegrin
(DC-SIGN) is a receptor that is mainly expressed on immature
dendritic cells (iDCs),11 and modulates the uptake of specific
pathogens through its interactions with mannosylated struc-
tures.12−14 Indeed, several studies reported that DC-SIGN
receptors can be targeted by using mannosylated structures.15−17
Discovery of human cancer antigens enabled scientists to
develop new immunotherapy strategies.18,19 Melanoma is often an
intractable cancer type and has been reported to be a promising
target for immunotherapy.20 GM3 ganglioside is a widespread
glycosphingolipid overexpressed in metastatic melanoma cells, and
several studies investigated its potential as a melanoma associated
antigen.21 A metabolite of GM3 ganglioside, GM3 lactone, is also
present in melanoma cells. Even though it is more immunogenic
than GM3 ganglioside, its amount is generally not sufficient to
cause an efficient immune response because of its instability in
acidic tumor environment. Previously, it was shown that a
permannosylated dendron-containing hydrolytically stable mimetic
of GM3 lactone (antigenic GM3 lactone mimetic) is able to
induce DC activation through DC-SIGN receptor.15
Recently, antigens delivered through nanoscale materials have
been shown to provide considerable advantages over soluble
antigen administration, due to the stimulation of antigen uptake
and cellular activation by surface-functionalized delivery vectors.
Gold and PLGA nanoparticles, dendrimers and liposomes
have previously been functionalized for in vitro dendritic cell
targeting purposes.15,22,23 Molecular self-assembly is a process
by which molecules are organized into complex structures
through noncovalent interactions. Functional self-assembled
nanomaterials can be designed through a bottom-up fabrication
technique,24,25 which can be used in many biomedical applica-
tions such as drug delivery and regenerative medicine.26,27
Among these materials, self-assembling peptide amphiphiles
(PA) have been extensively used for their biocompatibility and
biodegradability.28 In addition, these molecules can be designed
to form nanofibers and can be tailored with a variety of func-
tional groups and residues for cellular targeting.29,30
Here self-assembled mannosylated glycopeptide nanofibers
were used for the delivery of an immunogenic mimetic of
the GM3 lactone antigen. Sugar specificity was investigated
between mannose and glucose in terms of DC-SIGN receptor
targeting and antigen delivery into immature DCs. We showed
the activation and maturation of DCs in terms of phenotypic
expression of surface costimulatory molecules and morpho-
logical changes upon DC-SIGN targeting.
■ RESULTS AND DISCUSSION
Preparation of Fluorescent GM3-MIM Integrated
Glycopeptide Nanofibers. A glycosylated amino acid residue
was first synthesized in four steps prior to the synthesis of
glycopeptide PA molecules (Scheme S1). All compounds
synthesized in each step and the final molecule, Fmoc-L-Ser[α-
D-Man(OAc)4]−OH, were characterized by NMR and mass
spectrometry (Figures S1−S8). Synthesized Fmoc-L-Ser[α-D-
Man(OAc)4]−OH was used as the first amino acid residue of
the glycopeptide sequence during the elongation of the peptide
on solid support. After the resin cleavage, the amphiphilic
glycopeptide was obtained in protected form due to the
acetylated sugar hydroxyl groups, and deprotection reaction
was carried out in solution phase to prevent O-glycosidic
bond cleavage during acid treatment in solid phase peptide
synthesis.31 Although the mannosylated amino acid residue
existed at the C-terminus of the peptide segment, amphiphilic
character was obtained by the conjugation of a hydrocarbon tail
to the N-terminus of the peptide moiety (Figure 1). Here the
mannose residue was chosen because of its high affinity to
DC-SIGN receptor, enabling the induction of DC activation.
In addition, an additional glycopeptide molecule, Glc-PA, was
synthesized by using a glucosylated serine amino acid in the
sequence to test the sugar specificity of the glycosylated PA.
The chemical structures of the two amphiphilic glycopeptide
molecules, Man-PA and Glc-PA, were verified by liquid
chromatography and mass spectrometry (Figure S9).
Before the integration of fluorescent GM3-MIM into the
glycopeptide systems, the amphiphilic glycopeptides were
individually investigated in terms of their secondary structure
and morphological properties at physiological pH. Diluted
solutions of Man-PA and Glc-PA were studied by circular
dichroism (CD) spectroscopy and the results revealed that
both pure systems were oriented in a β-sheet conformation,
exhibiting a positive peak at 202 nm and negative peak at
Figure 1. Chemical structures of the self-assembling molecules.
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218 nm (Figure S13). Morphological observations were also
carried out under scanning transmission electron microscopy
(STEM) and both glycopeptide samples, regardless of the type
of sugar they contain, were found to form high-aspect-ratio
nanofibers with diameters on the order of 9−11 nm and lengths
reaching several micrometers (Figures S14A, B).
Because of its poor solubility in water, the integration of
GM3-MIM into the glycopeptide nanofibers was achieved by
solvent exchange (Figure 2). Although amphiphilic glycopeptide
solutions were dissolved in slightly acidic water, GM3-MIM was
solubilized in a DCM:MeOH (7:1, v/v %) mixture. Prior to the
addition of the GM3-MIM solution, glycopeptide solutions were
separately sonicated at 50 °C at pH 6 to disrupt self-assembly
and generate single glycopeptide molecules. The glycopeptides
carry a positive net charge from their lysine residue, which
increases their water solubility and facilitates their integration
during self-assembly, as electrostatic interactions force the
hydrophobic tail of glyco-PAs within the nanofiber structure,
whereas lysine and serine-conjugated glucose/mannose residues
are presented at the nanofiber periphery. After addition of
the antigen solution, heating and sonication processes allow the
hydrophobic tail region of GM3-MIM to interact with the
hydrocarbon chain segment and hydrophobic amino acids of
glycopeptides, which facilitates the transfer of GM3-MIM into
the aqueous environment. In addition, as GM3-MIM exhibits
a similar amphiphilic structure, it is likely that the molecule
also participates in nanofiber assembly with its hydrophobic tail
facing to the nanofiber core and hydrophilic ring structure facing
to the hydrophobic environment.
Photographs taken before and after solvent exchange
confirmed the transfer of GM3-MIM molecule, as BODIPY-
tagged GM3-MIM could no longer be observed in the DCM
phase following the exchange (Figure 2A). Spectroscopic analyses
were also conducted to verify the transfer of GM3-MIM
molecule into the water phase. The fluorescence and UV spectra
of fluorescent GM3-MIM integrated glycopeptide systems were
blue-shifted relative to GM3-MIM alone, which was also in good
agreement with visual observations (Figures 2B, C). UV spectra
results also showed that GM3-MIM exhibited comparable
absorbance values before and after its integration into glyco-
PAs, suggesting that it was successfully integrated into the PA
system and that integration was quantitative.
The successful transfer of GM3-MIM into the glycopeptide
solutions was followed by the investigation of the secondary
structure and morphology of glycopeptides in the presence
of the antigen by using CD and STEM, respectively. CD results
indicated that GM3-MIM integrated glycopeptide solutions
showed a β-sheet composition (Figure S13). Although a higher
degree of bundling was observed after the integration in STEM
images, the PAs nevertheless self-assembled into nanofibers
without any significant change in their diameters, indicating the
preservation of the PA packing process (Figures 3A, B). More-
over, because of the sulfur content of GM3-MIM molecule, it
was possible to test whether the antigen was successfully
integrated into the glycopeptide nanofibers. Sulfur and oxygen
mapping was performed under TEM to confirm that GM3-MIM
molecules were present in glycopeptide nanofibers (Figure S15).
In addition, zeta potential measurements were performed in
order to investigate the surface charge of the glyco-PAs, which
was found to be around +27 mV (Figure S16).
Cell Viability Assay and iDC Differentiation from THP-1
Monocytes. Cytotoxicity is another key factor when designing
materials for targeting purposes, and according to live−dead
assay, 150 μM of glycopeptide nanofibers were found to
be nontoxic to cells (Figure S17). Immature dendritic cells
were obtained from THP-1 human monocytes as previously
reported.32 Cells differentiation was monitored by quantifying
the surface expression of CD86, and flow cytometry analyses
were performed to confirm the de novo expression of this
marker (Figure S18A). In addition, the cells displayed extrusions
and protrusions that are consistent with the typical morphology
of immature dendritic cells (Figure S18B). As glyco-PAs are
biocompatible at 150 μM, and they formed nanofibers at this
concentration (as confirmed by TEM and CD), subsequent
in vitro experiments were performed using this concentration.
Internalization of Fluorescent GM3-MIM Integrated
Glycopeptide Nanofibers. Previous studies have reported
the internalization of mannosylated structures through
DC-SIGN receptors. Considering that iDCs strongly express
DC-SIGN on their surfaces,11 we investigated the internal-
ization of GM3-MIM integrated glycopeptide nanofibers
through confocal microscopy imaging after obtaining iDCs
from THP-1 monocytes. The charge of a material has a critical
influence over internalization, and it is feasible that different
Figure 2. (A) Image of solvent exchange (DCM:H2O) for GM3-MIM
molecule. (B) Fluorescence and (C) UV spectra of GM3-MIM and
GM3-MIM integrated glycopeptide solutions dissolved in
DCM:MeOH (7:1) and water, respectively.
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surface charges could alter the uptake of otherwise similar
PA structure.33 However, Zeta potential results indicated that
Man-PA and Glc-PA had similar charges at around +27 mV
(Figure S16), suggesting that any possible difference in the
uptake would not be caused by surface charge.
Cells were treated with Man-PA/GM3-MIM, Glc-PA/
GM3-MIM or control GM3-MIM for 24 h. BODIPY-conjugated
GM3-MIM was used for internalization analyses, and cells were
also stained with phalloidin and To-Pro for cytoskeletal and
nuclear staining, respectively. Confocal imaging indicated that,
under Man-PA/GM3-MIM treatment, antigen uptake was higher
compared to other groups (Figure 4A). This uptake can be
attributed to the high affinity of mannose to DC-SIGN, and
induced maturation as observed by changes in cell morphology.
However, Glc-PA/GM3-MIM was internalized only to a lesser
extent, and could not promote an mDC-like morphology as
well as Man-PA/GM3-MIM (Figure 4B). However, the uptake
of Glc-PA/GM3-MIM was nevertheless higher compared to the
control, GM3-MIM (Figure 4C). Complementary results were
also obtained quantitatively through flow cytometry analyses.
Man-PA/GM3-MIM showed 1.5-fold higher uptake compared
to Glc-PA/GM3-MIM and almost 7-fold higher uptake
compared to GM3-MIM (Figure S19). Glc-PA/GM3-MIM
showed 6-fold higher uptake compared to GM3-MIM
(Figure S19). This can be explained by the positive charge of
Man-PA and Glc-PA (GM3-MIM has no charge) and by the
ability of nanofiber structure to promote endocytosis.
Surface Marker Analyses of Dendritic Cell Activation.
Activation and maturation state of DCs were measured by
analyzing the expression of CD86, CD83 and MHC-II receptors.
Increased expression of these molecules was previously shown
to be associated with the maturation and activation status of
dendritic cells.15,34 CD86 is a costimulatory molecule interacting
with CD28 on T cells and is required for proper activation.35
Man-PA/GM3-MIM group significantly increased the expression
of CD86 compared to other groups as measured by flow
cytometry (Figure 5A). CD83 is another activation marker for
DCs and its expression is up-regulated during the transition
from immature state to mature state.36,37 Man-PA/GM3-MIM
also significantly increased the expression of CD83 compared to
the other compounds (Figure 5B), and the same pattern was
observed for the expression of MHC-II (Figure 5C), which is a
molecule essential for the proper presentation of antigens.38
Expression profiles obtained by flow cytometry analysis were
compatible with fluorescent imaging (Figure 4) and flow
cytometry analyses (Figure S19) of GM3-MIM internalization.
In summary, considering the necessity of the up-regulation of
these molecules for DC activation and maturation, Man-PA/
GM3-MIM was shown to have a significant role in inducing the
activation and maturation of DCs in terms of surface expression
of CD86, CD83, and MHC-II.
Morphological Analyses of Dendritic Cell Activation.
Morphological analyses were carried out using scanning electron
microscopy (SEM) to investigate the changes in surface area
and cellular size. In agreement with fluorescent imaging data
(Figure 4), iDCs treated with Man-PA/GM3-MIM increased
their surface area and morphologically became more mDC-like
(Figure 6A) compared to Glc-PA/GM3-MIM (Figure 6B) and
GM3-MIM (Figure 6C). It should be noted that increases in
surface area facilitate the interaction of DCs with surrounding
cells, and are therefore important for antigen presentation.8
Man-PA and Glc-PA nanofibers lacking GM3-MIM integration were
also tested for morphological analyses to ensure that the changes
were due to GM3-MIM delivery. According to SEM images,
Figure 3. STEM images of (A) Man-PA/GM3-MIM and (B) Glc-PA/GM3-MIM.
Figure 4. Uptake of BODIPY conjugated GM3-MIM and morphological changes of iDCs when treated with (A) Man-PA/GM3-MIM,
(B) Glc-PA/GM3-MIM, and (C) only GM3-MIM for 24 h. Nuclei were stained with To-Pro (blue), cytoskeletons were stained with Phalloidin
(red) and BODIPY green (GM3-MIM). Scale bars: 20 μm.
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Man-PA (Figure S20A) and Glc-PA (Figure S20B) did not have any
effect on morphological changes in iDCs, indicating the dominant
effect of the antigen delivery through Man-PA/GM3-MIM.
■ CONCLUSION
In this study, peptide amphiphile molecules presenting mannose
moieties were used for the targeting of the DC-SIGN receptor
and the delivery of an immunogenic mimetic of GM3-lactone
antigen to induce DC maturation and activation. GM3-MIM
presented on Man-PA nanofibers were more efficient over
Glc-PA/GM3-MIM and GM3-MIM in terms of antigen inter-
nalization, stimulation of CD86, CD83, and MHC-II expression
and the induction of a mature DC-like morphology, suggesting
that mannose/DC-SIGN interactions are primarily responsible
for uptake. Considering the instability of GM3 lactone molecule
and its low concentration under physiological conditions,
Man-PA is a promising delivery vehicle for the internalization
of this immunogenic antigen through DC-SIGN receptors.
We show that the targeted delivery of antigens by using Man-PA
to activate iDCs can play important roles in inducing cellular
immunity against cancer conditions, and that correctly delivered
GM3-MIM can be suitably presented to the immune system.
Peptide amphiphiles are biocompatible and biodegradable
materials with a broad range of potential applications for tissue-
specific targeting and delivery. Unlike conventional delivery
vesicles, such as liposomes, PA systems can be functionalized with
targeting molecules and can naturally localize to tissues of interest
because of the bioactive epitopes expressed on their surfaces.
These epitope sequences can also be designed to interact with
specific cell surface receptors, promoting entry into target cell
types. In the present study, the integration of GM3-MIM into
the peptide nanofiber structure enabled efficient internalization
of the molecule. Considering that highly mannosylated struc-
tures are suitable candidates for DC-SIGN receptor targeting,
using sugar moieties for delivery purposes hold high potential
for future studies.
■ EXPERIMENTAL SECTION
Materials. 9-Fluorenylmethoxycarbonyl (Fmoc) protected amino
acids, [4-[α-(2′,4′-dimethoxyphenyl) Fmoc aminomethyl] phenoxy]
acetamidonorleucyl-MBHA resin (Rink amide MBHA resin) and
2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophos-
phate (HBTU) were purchased from NovaBiochem. Fmoc-Ser[β-D-
Glc(OAc)4]−OH was purchased from AAPPTec. Lauric acid and
N,N- diisopropylethylamine (DIEA) were purchased from Merck.
Other chemicals were purchased from Alfa Aesar or Sigma-Aldrich
and used without any purification. Deionized water (resistance of
18 MΩ cm) was used during the experiments.
Synthesis of N-(9-Fluorenylmethoxycarbonyl)-L-serine allyl ester
(3). Protection of the carboxylic acid of Fmoc-Ser-OH to produce
Fmoc-L-Ser-OAll resulted in 86% yield. Fmoc-Ser-OH (1) (1.5 g,
4.5 mmol) was dissolved in DMF and mixed with allyl bromide
(2.14 mL, 5.4 mmol) in the presence of K2CO3 (0.93 g, 6.75 mmol).
The reaction was allowed to stay for 24 h at room temperature.
After CH2Cl2 addition, the mixture was extracted with water and brine
solution. Aqueous phase was discarded and Na2SO4 was added into
organic phase. The solution was concentrated with rotary evaporator
and purified using flash column chromatography (1:1 nHex/EtOAc).
1H NMR (400 MHz, CDCl3) δ (ppm) = 7.79 (d, J = 7.5 Hz, 2H), 7.63
(d, J = 6.7 Hz, 2H), 7.43 (t, J = 7.5 Hz, 2H), 7.34 (tt, J = 1.1, 7.5 Hz,
2H), 6.02−5.85 (m, 1H), 5.75 (d, J = 6.0 Hz, 1H), 5.37 (dd, J = 1.1,
17.2 Hz, 1H), 5.29 (dd, J = 1.1, 10.4 Hz, 1H), 4.72 (d, J = 2.3 Hz, 1H),
4.55−4.41 (m, 3H), 4.26 (t, J = 6.9 Hz, 1H), 4.10−3.92 (m, 2H). 13C
NMR (100 MHz, CDCl3) δ (ppm) = 170 0.12, 156.23, 143.69, 141.37,
141.33, 131.32, 127.75, 127.10, 125.06, 119.99, 119.04, 67.22, 66.36,
61.89, 56.13, 47.19. NMR data were in agreement with those reported
Figure 5. Surface expression MFI values of (A) CD86, (B) CD83, and
(C) MHC-II under Man-PA/GM3-MIM, Glc-PA/GM3-MIM, and
only GM3-MIM treatment for 24 h. Values represent mean ± SEM
(****p < 0.0001).
Figure 6. Morphological analyses of the differentiation in iDCs when treated with (A) Man-PA/GM3-MIM, (B) Glc-PA/GM3-MIM, and
(C) GM3-MIM for 24 h. Scale bars are 30 μm.
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in the literature.39 ESI-TOF-HR-MS m/z calcd for C21H21NO5
[M + Na]+ 390.1420; found 390.1363, [2M+Na]+ 757.2814.
Synthesis of 1,2,3,4,6-Penta-O-acetyl-D-mannopyranose (4).
Acetylation of D-mannose resulted in 93% yield. Three grams of
D-mannose (2) (1 equiv.) was dissolved in pyridine (4 mL) and 15 mL
of acetic anhydride (10 equiv.) was added into the solution. The
reaction was kept at room temperature and stirred overnight. Pyridine
was evaporated and kept under vacuum for 3−4 h. The product was
purified by column chromatography (1:1 n-Hex:EtOAc, Rf = 0.45)
1H NMR (400 MHz, CDCl3, mixture of both anomers): signals of
β-anomer δ (ppm) = 6.11 (d, J = 1.8 Hz, 1H), 5.38−5.36 (m, 2H),
5.28 (d, J = 2.0 Hz, 1H), 4.30 (dd, J = 4.9, 12.4 Hz, 1H), 4.18−4.15
(m, 1H), 4.08 (dd, J = 2.4, 12.4 Hz, 1H), 2.20 (s, 3H), 2.19 (s, 3H),
2.11 (s, 3H), 2.07 (s, 3H), 2.03 (s, 3H); signals of α-anomer
δ (ppm) = 5.87 (d, J = 1.2 Hz, 1H), 5.51 (dd, J = 1.1, 3.3 Hz, 1H),
5.31 (t, J = 10.0 Hz, 1H), 5.15 (dd, J = 3.3, 10.0 Hz, 1H), 4.32 (dd,
J = 5.3, 12.4 Hz, 1H), 4.07 (dd, J = 2.4, 12.4 Hz, 1H), 3.83 (ddd, J =
2.4, 5.3, 9.8 Hz, 1H), 2.19 (s, 3H), 2.12 (s, 3H), 2.07 (s, 3H), 2.06 (s,
3H), 2.02 (s, 3H); 13C NMR (100 MHz, CDCl3, mixture of both
anomers) δ (ppm) = 170.58, 170.14, 169.93, 169.68, 169.53, 169.49,
168.00, 90.64, 90.44, 73.34, 70.65, 68.75, 68.36, 68.19, 65.81, 65.61,
65.48, 62.13, 62.09, 21.00, 20.81, 20.71, 20.70, 20.67, 20.66, 20.62,
20.61, 20.59, 20.49. NMR data were in agreement with those reported
in the literature.40 ESI-TOF-HRMS m/z calculated for C16H22O11
[M + Na]+ 413.1162; found 413.1064.
Synthesis of N-(9-Fluorenylmethoxycarbonyl)-3-O-(2,3,4,6-tetra-
O-acetyl-α-D-mannopyranosyl)-L-serine Allyl Ester (5). D-Mannose
pentaacetate coupling to Fmoc-L-Ser-O. All to produce Fmoc-L-
Ser[α-D-Man(OAc4)]-O. All resulted in 40% yield. The Lewis acid,
BF3·Et2O (8 mL, 0.3 mmol), was added to the mannose pentaacetate
(4) (1.3 equiv., 4 g) and N-α-Fmoc-Ser-OAll (3) (1 equiv., 2.9 g) in
dry CH2Cl2 under argon atmosphere. The reaction was cooled to 0 °C
for Lewis acid addition, after 5−10 min reaction was allowed to stay at
room temperature for 12 h. The progress of the glycosylation reaction
was monitored by TLC (2:3 nHex/EtOAc). The solution was diluted
with CH2Cl2 and extraction was done with water (3 times). Na2SO4
was added to remove trace amounts of water and the solution was
concentrated in a rotary evaporator. Compound was purified with
column chromatography (2:3 nHex/EtOAc, Rf = 0.3). 1H NMR
(400 MHz, CDCl3) δ (ppm) = 7.79 (d, J = 7.5 Hz, 2H), 7.65 (d, J =
7.3 Hz, 2H), 7.42 (t, J = 7.3 Hz, 2H), 7.34 (t, J = 7.4 Hz, 2H), 6.01−
5.92 (m, 1H), 5.90 (d, J = 7.8 Hz, 1H), 5.39−5.36 (m, 1H), 5.34−5.27
(m, 3H), 5.22 (brs, 1H), 4.82 (s, 1H), 4.77−4.69 (m, 2H), 4.65−4.60
(m, 1H), 4.43 (d, J = 7.1 Hz, 2H), 4.29−4.23 (m, 2H), 4.15−4.12 (m,
1H), 4.11−4.07 (m, 1H), 4.04−3.97 (m, 2H), 2.19 (s, 3H), 2.09 (s,
3H), 2.04 (s, 3H), 2.01 (s, 3H). 13C NMR (100 MHz, CDCl3) δ
(ppm) = 170.57, 169.91, 169.75, 169.69, 155.84, 148.98, 148.28,
143.77, 141.30, 131.24, 127.92, 127.76, 127.11, 125.15, 120.32, 120.01,
119.55, 98.58, 90.62, 70.63, 69.68, 69.19, 68.78, 68.35, 66.62, 65.98,
62.35, 62.12, 60.37, 54.43, 47.11, 20.82, 20.68, 20.65, 20.63. NMR data
were in agreement with those reported in the literature.41 ESI-TOF-
HRMS m/z calculated for C35H39NO14 [M + H]
+ 698.2371; found
698.2002, [M + Na]+ 720.1802, [M+K]+ 736.1543.
Synthesis of N-(9-Fluorenylmethoxycarbonyl)-3-O-(2,3,4,6-tetra-
O-acetyl-α-D-mannopyranosyl)-L-serine (6). Deprotection of allyl
group for production of Fmoc-L-Ser[α-Man(OAc)4]−OH resulted
in 72% yield. Glycosylated amino acid (5) (4.02 mmol, 2.8 g),
N-methylaniline (40.68 mmol, 4.40 mL), and Pd(PPh3)4 (0.048 mmol,
55 mg) were dissolved in THF. The reaction took place at room
temperature under argon overnight and monitored with TLC
(98:2, DCM:AcOH). The compound was concentrated with rotary
evaporator and the product was purified with column chromatography
(1:1 nHex/EtOAc). 1H NMR (400 MHz, CDCl3) δ (ppm) = 7.78 (d,
J = 7.5 Hz, 2H), 7.63 (t, J = 6.7 Hz, 2H), 7.41 (t, J = 7.4 Hz, 2H), 7.32
(t, J= 7.4 Hz, 2H), 6.46 (d, J = 7.7 Hz, 1H), 5.45 (dd, J = 3.0, 10.0 Hz,
1H), 5.33−5.25 (m, 2H), 4.88 (brs, 1H), 4.71 (d, J = 8.0 Hz, 1H), 4.45
(dd, J = 7.5, 10.4 Hz, 1H), 4.39−4.33 (m, 1H), 4.29 (d, J = 5.5 Hz,
1H), 4.27−4.21 (m, 2H), 4.18−4.12 (m, 2H), 4.10−4.06 (m, 2H),
2.18 (s, 3H), 2.08 (s, 3H), 2.04 (s, 3H), 2.00 (s, 3H)). 13C NMR
(100 MHz, CDCl3) δ (ppm) = 171.82, 170.73, 170.68, 170.20,
169.82, 156.03, 143.81, 143.76, 141.30, 141.28, 127.93, 127.74, 127.09,
125.22, 125.15, 121.48, 120.33, 120.00, 98.13, 69.40, 69.34, 69.02,
68.93, 67.34, 66.16, 62.33, 54.05, 47.12, 20.85, 20.79, 20.67, 20.62.
NMR data were in agreement with those reported in the literature.41
ESI-TOF-HRMS m/z calculated for C32H35NO14 [M-H]
− 656.2058;
found 656.1897, [2M-H]− 1313.3849.
Synthesis of Amphiphilic Glycopeptides. Protected glycopep-
tides (Man-PA and Glc-PA) were constructed on MHBA Rink
Amide resin. All amino acid couplings were performed with 2 equiv of
Fmoc protected amino acid, 1.95 equiv of HBTU and 3 equiv of
N,N-diisopropylethylamine (DIEA) in DMF for 3 h. Fmoc removals
were performed with 20% piperidine/dimethylformamide (DMF)
solution for 20 min. Cleavage of the peptides from the resin and
deprotection of acid labile protecting groups were carried out with a
mixture of trifluoroacetic acid (TFA):triisopropyl silane (TIS):water in
the ratio of 95:2.5:2.5 for 2 h. Excess TFA was removed by rotary
evaporation. The remaining residue was triturated with ice-cold diethyl
ether and the resulting white pellet was freeze-dried. Deacetylation
reaction was carried out in solution. For the cleavage of acetyl groups,
210 mg of protected glycopeptide (1 equiv.) was dissolved in 105 mL
of anhydrous methanol. Two moles of NaOMe (4.4 equiv.) was
dissolved in methanol and poured into the solution. After adjusting pH
to 8−8.5, the reaction was carried out at room temperature for 2−3 h.
The solution was neutralized with a few drops of acetic acid in order
to terminate the reaction. The solvent was removed by vacuum.
After water addition, it was frozen at −80 °C and freeze-dried. Before
and after the deacetylation reaction, glycopeptides were identified and
analyzed by reverse phase HPLC on an Agilent 6530 accurate-Mass
Q-TOF LC/MS equipped with an Agilent 1200 HPLC. A
Phenomenex Luna C8 100A (50 × 3.00 mm) column as stationary
phase and water/acetonitrile gradient with 0.1% formic acid as mobile
phase were used to identify the peptide amphiphile. They were purified
on Agilent 1200 by using a Zorbax prepHT 300CB-C8 column with a
water−acetonitrile (0.1% TFA) gradient.
Synthesis of Fluorescent GM3-MIM ® (GM3-MIM-BODIPY).
The alkyl derivative of GM3-MIM was prepared according to the
previously reported procedure.42 For the synthesis of the fluorescent
derivative of GM3-MIM, the procedure is described below: To a
stirred solution of amino alkyl MIM-GM3 (17.8 mg, 0.037 mmol) in a
mixture of DMF:H2O (4:1, 1 mL) were added NaHCO3 (4.3 mg,
0.052 mmol) and BODIPY-NHS ester (20.2 mg, 0.052 mmol).
The reaction mixture was stirred for 18 h at room temperature, then
concentrated to dryness. The crude was purified by flash chromatog-
raphy on silica gel (eluent: CH2Cl2:MeOH 5:1) to afford GM3-MIM-
BODIPY as a glassy brown solid (24.0 mg, 0.032 mmol, 86%). [α]D
22=
−54.3 (c 0.41, CH3OH); 1H NMR (500 MHz, CD3OD) δ 7.44 (s,
H-b8), 7.03 (d, J = 3.9 Hz, H-b2), 6.34 (d, J = 3.9 Hz, H-b3), 6.23 (s,
H-b6), 4.98 (s, H-a), 4.18−4.15 (m, H-3), 4.10−4.08 (m, H-e), 4.04
(ad, J = 2.2 Hz, H-4), 3.96 (ad, J = 9.6 Hz, H-5), 3.83−3−64 (m, 7H,
H-xa, H-f, H-d, H-6, H-7), 3.52−3.47 (m, 1H, H-xb), 3.24 (t, J =
7.5 Hz, 2H, H-w), 3.19 (t, J = 6.8 Hz, 2H, H-y), 3.04−3.02 (part A of
an AB system, JA‑B = 12.8 Hz, H-1’a), 3.0−2.97 (part B of an AB
system, JB‑A = 12.8 Hz, H-1’b), 2.62 (t, J = 7.5 Hz, 2H, H-z), 2.53 (s,
3H, CH3), 2.30 (s, 3H, CH3), 1.95−1.93 (m, 2H, H-2), 1.63−1.30 (m,
8H, CH2).
13C NMR (125 MHz, CD3OD) δ 173.1 (Cq), 159.9 (Cq),
157.1 (Cq), 144.4 (Cq), 141.8 (Cq), 135.1 (Cq), 133.5 (Cq), 128.2
(C-b1), 124.4 (C-b8), 119.9 (C-b6), 116.3 (C-b2), 106.4 (Cq), 96.3
(C-a), 92.3 (C-1), 72.5 (C-e), 70.9 (C-5), 68.4 (C-d), 67.8 (C-x), 66.4
(C-4), 66.2 (C-3), 64.5 (C-6), 62.8 (C-7), 61.0 (C-f), 39.0 (C-y), 36.2
(C-2), 34.7 (C-w), 33.2 (C-1’), 29.1, 28.9, 26.3, 25.6 (CH2), 24.3
(C-z), 13.5, 9.8 (CH3); HRMS: m/z calcd for C34H47O11N3BF2S
[M-H]− 753.30274, found 753.30342. Characterizations of fluorescent
GM3-MIM (GM3-MIM-BODIPY) are shown in Figures S10−S12.
Preparation of Fluorescent GM3-MIM Integrated Glycopep-
tide Nanofibers. One mM of Man-PA and Glc-PA (2 mL) were
dissolved in water and heated up to 50 °C during sonication. 1.33 mM
of GM3-MIM was dissolved in DCM:MeOH mixture (7:1 v/v %,
610 μL) and added into each glycopeptide solution. They were
sonicated and vortexed for an hour at 50 °C. Although the mixture
was initially turbid, it became transparent as the solvents evaporated.
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Final GM3-MIM concentration to PA concentration ratio was adjusted
to 1:2.5.
Characterization of Fluorescent GM3-MIM Integrated Gly-
copeptide Nanofibers. Fluorescence spectra of GM3-MIM and
GM3-MIM integrated glycopeptide nanofibers were recorded by a
Varian Cary Eclipse spectrophotometer with an excitation wavelength
of 503 nm. Varian Cary 100 UV−vis spectrophotometer was used to
record absorption spectra of GM3-MIM-BODIPY and GM3-MIM
integrated glycopeptide nanofibers. For UV and fluorescence measure-
ments, DCM:MeOH mixture (7:1, v/v %) was used to dissolve GM3-
MIM-BODIPY, and water was used as the solvent for GM3-MIM
integrated glycopeptide nanofibers. A Jasco J-815 CD spectropho-
tometer was used to investigate the secondary structures of PA
molecules and GM3-MIM integrated PA nanofibers. All samples were
measured at physiological pH at 0.25 mM concentration. 300 μL of
the sample was transferred into a 1 mm quartz cuvette and spectra
were obtained at room temperature from 300 to 190 nm with a data
interval of 1 nm and a scanning speed of 100 nm/min. TEM images
were obtained with a FEI Tecnai G2 F30 TEM at 200 kV. A high-angle
annular dark field (HAADF) detector was used for images taken in
STEM mode. One mM of Glc-PA, Man-PA and GM3-MIM integrated
glycopeptide nanofiber systems were first diluted to 150 μM and then
dropped on 300-mesh carbon TEM grids. Samples were allowed to
stay at room temperature for 3 min, stained by 2 wt % uranyl-acetate
staining for another 1−2 min and air-dried prior to STEM imaging.
Zeta potential of the nanofibers was measured by ZetaSizer. A Malvern
Nanosizer/ZetaSizer Nano-ZS ZEN 3600 (Malvern Instruments,
USA) instrument was used for the analysis. Measurements were per-
formed in quartz cuvettes and repeated at least three times. Samples
were prepared by dissolving each component in water at a concentra-
tion of 0.25 mM.
Cellular Viability. THP-1 human monocytes were kindly provided
by Prof. E. Erbay of Bilkent University. Cells were seeded onto 96 well
plates at a density of 5000 cells/well within media containing Man-PA
and Glc-PA. Viability was assessed at 150 μM and 250 μM for both
peptide molecules. At the end of 24 h, cells were washed with 1× PBS
and were stained with Calcein-AM and ethidium homodimer for
30 min at room temperature in dark. Then, images of the cells were
taken and quantified by using ImageJ program.
Differentiation of THP-1 Human Monocytes into Immature
Dendritic Cells. THP-1 human monocyte cell line was differentiated
into immature dendritic cells in RPMI medium containing 10% FBS,
rhIL-4 (100 ng/mL), and rhGM-CSF (100 ng/mL) for 5 days. Medium
was exchanged with fresh cytokines after 2 days.
Internalization of Fluorescent GM3-MIM Integrated Glyco-
peptide Nanofibers. Thirteen mm glass coverslips were placed in
24-well plates and 5 × 104 THP-1 cells were seeded and differentiated
into immature dendritic cells as previously stated. After 5 days, the
PA molecules were administered and cells were incubated for 24 h.
After incubation, cells were washed with PBS two times, fixed with 4%
paraformaldehyde, and permeabilized with 3% Triton-X and stained
with phalloidin and TO-PRO-3. Cells were visualized by using Laser
Scanning Confocal Microscope (LSM 510, Zeiss).
Surface Marker Analyses of Dendritic Cell Activation. iDCs
were obtained from THP-1 monocytes as mentioned above. At the
end of 5 days, cells were treated with Man-PA, Glc-PA, Man-PA/
GM3-MIM, Glc-PA/GM3-MIM, and only GM3-MIM for 24 h. Total
peptide concentration for each group was 150 μM and GM3-MIM
amount was 40 μg. At the end of 24 h, media were discarded, cells
were centrifuged at 2500 rpm for 5 min and washed with 1× PBS and
then centrifuged again. Then, pellet was dissolved in 1× PBS and
cells were stained with CD86 (PerCP), CD83 (Phycoerythrin)
and HLA-DR (MHC-II) (PE/Cy5) antibodies for 15 min at room
temperature. 10 000 cells were recorded for each condition during flow
cytometry analyses.
Scanning Electron Microscopy (SEM) Imaging. SEM imaging
was carried out in order to evaluate the morphological changes during
dendritic cell maturation. 5 ×104 THP-1 cells were seeded onto
coverslips in 24-well plates and differentiated into immature DCs as
previously stated. Treatment was carried out for 24 h and at the end
of 24 h cells were washed once with 1× PBS, fixed with 2%
gluteraldehyde/PBS and 1 wt % OsO4 for 1 h each. After fixation, cells
were washed with ddH2O and dehydrated by using increasing ethanol
concentrations; 20, 40, 60, 80, and 100% v/v. Critical point dryer
(Autosamdri 815B equipment from Tousimis) was used afterward
and coverslips were coated with 4 nm Au/Pd. SEM (FEI Quanta
200 FEG) images were taken through using Everhart−Thornley
Detector (ETD) at high vacuum mode at 5 keV beam energy.
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